EQS-News: How Kamada (NASDAQ: KMDA) Is Transforming Its Strategic Focus Into Commercial Growth

By JE Insights, Benzinga

DETROIT, MICHIGAN - February 28, 2025 (NEWMEDIAWIRE) - Although advancements in the broader healthcare ecosystem have delivered countless life-saving solutions, there remain significant unmet medical needs. As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, Kamada Ltd (NASDAQ: KMDA), plays an important role in helping address rare and severe medical conditions.

Although the broader category of plasma biologics commands a well-established legacy, modern applications of plasma-derived therapies have dramatically elevated the discipline. While the global plasma protein therapeutics market reached a valuation of $28.2 billion in 2022, Kamada is hoping to fill the gaps in the industry and is focused on the development of therapeutics for which there are limited solutions offered by other companies, if any.

As Kamada knows, a pivotal reason why plasma protein and immunoglobulin therapeutics are crucial in the broader healthcare landscape is that they often represent the only treatment option available for rare, chronic and life-threatening conditions. Some examples of these disorders are:

• Post-exposure complications: Products such as human rabies immunoglobulin (HRIG), which is one of Kamada's leading products, help prevent deadly infections.

• Organ transplants and immune modulation: Kamada has spearheaded efforts to provide immunoglobulin products that prevent complications resulting from cytomegalovirus (CMV) infections, a leading cause of organ rejection in transplant patients, and hepatitis B virus (HBV) recurrence following liver transplantation. 

• Alpha-1 antitrypsin deficiency (AATD): Another specialty for Kamada, plasma-derived AAT therapy slows down lung damage tied to a deficiency of the alpha-1 antitrypsin protein through augmentation therapy which is currently the only specific therapy for lung disease caused by AATD.

As an expert in the field of specialty plasma therapies, Kamada reports achieving success thanks to its diverse commercial portfolio, advanced pipeline and vertical integration. So far, the U.S. Food and Drug Administration (FDA) has approved six of the company’s plasma-derived therapeutics, which target rare and underserved conditions such as rabies, AATD and infectious diseases after solid organ transplantation, such as CMV and HBV.

Moreover, Kamada is advancing a phase 3 pivotal trial for its inhaled alpha-1 antitrypsin (AAT) therapy. AATD is a genetic disorder that results in a deficiency of the alpha-1 antitrypsin protein, which can lead to lung damage and chronic obstructive pulmonary disease (COPD). A fundamental advantage of inhaled AAT therapy is that it is non-invasive, allowing patients to self-administer easily at home. This protocol eliminates the need for intravenous infusions.

Combined with the lower dosage of medicine (thus potentially improving COGS) and improved quality of life for patients, Kamada has hopes that pending regulatory approval, this proposed investigational solution will revolutionize the way AATD specialists and patients treat this chronic disease. Management is targeting the global market for AATD-related lung disease, predicted by a 2024 Cantor Fitzgerald report to reach $2 billion by 2029.

Kamada’s Commercial Growth

Kamada developed itself as a vertically integrated company through the establishment of a plasma-collection subsidiary, and commercial infrastructure in the U.S. and additional countries. By controlling key aspects of its value chain, Kamada says it has been able to streamline processes that are often fragmented in traditional biopharma models. Similar to Israeli-based pharmaceutical company, Teva Pharmaceutical Industries Ltd., Kamada says it is committed to using its strategic focus, operational excellence and vertical integration as a springboard to commercial growth.

Today, Kamada is evolving past its portfolio of drugs to expand into commercial operations. For example, the company is focused on developing its own plasma collection capabilities, which reduces some of the dependency on third-party suppliers and which it hopes will allow it to be a supplier for industry peers. As it stands, Kamada Plasma is one of a limited number of specialty plasma collection firms in the United States. According to the company, it is working to leverage its strong cash position to identify and secure future business developments and M&A opportunities, especially in the U.S. market. The company is also looking into exploring manufacturing agreements to produce plasma-derived solutions for other companies, which it believes would create additional revenue. 

During recent years, Kamada has consistently delivered growth in its financial results, supported by both its existing portfolio and ongoing strategic initiatives. For 2024, the company recently reaffirmed its guidance of revenues of $158 million to $162 million, with adjusted EBITDA in the range of $32 million to $35 million. The company is expecting to reach $178 to $182 million in revenue and $38 to $42 million of adjusted EBITDA in 2025. If this is accomplished, it would represent a year-over-year increase of 13% in revenue and 19% in adjusted EBITDA based on a mid-point of 2024 annual guidance. 

“We enter 2025 from a position of significant strength and are pleased with the progress made over the past year. We look forward to achieving our value-generating objectives for 2025 driven by our four strategic growth pillars, comprising of organic commercial growth, the execution of business development and M&A transactions, our plasma collection operations, and the further advancement of our pivotal phase 3 Inhaled AAT program,” shared Amir London, Kamada’s chief executive officer. “We expect continued double-digit profitable growth in 2025, driven by our diverse commercial portfolio marketed in over 30 countries.”

By focusing on areas of unmet medical needs, expanding its geographic footprint and distribution network while maintaining operational excellence, Kamada aims to ensure it remains a key player in a growing industry. With a proven track record and a commitment to innovation and excellence, the company seems poised to capitalize on emerging opportunities, delivering solutions for patients around the world.

Featured photo courtesy of Kamada

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Cautionary Note Regarding Forward-Looking Statements 

This post includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including (among others) statements regarding: 1) prospects of regulatory approval for our AATD treatment which our management targets as a $2 billion global market, 2) Kamada's focus on developing its own plasma collection capabilities to reduce third-party dependency and become a supplier of plasma-derived solutions for other companies to create additional revenues, 3) Kamada's intent to leverage its strong cash position to identify and secure future business developments and M&A opportunities, especially in the US market, 4) Kamada’s 2024 guidance of the $158-$162 million in revenues and $32-$35 in ETIBDA, 5) Kamada’s 2025 guidance of $178 – $182 Million in revenue and $38 -$42 million of adjusted EBITDA and if this is accomplished it would represent, a year-over-year increase of 13% in revenue and 19% in adjusted EBITDA based on a mid-point of 2024 annual guidance, and 6) Kamada’s expectations to continue double-digit profitable growth in 2025. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, conflicts in the Middle East and the impact of such conflicts, continued demand for Kamada’s products, financial conditions of the Company’s customers, suppliers and service providers, Kamada’s ability to leverage new business opportunities and integrate the new product portfolio into its current product portfolio, Kamada’s ability to reap the benefits of the acquisition and expansion of plasma collection centers, Kamada’s ability to continue enrollment of the pivotal Phase 3 InnovAATe clinical trial, unexpected results of clinical studies, Kamada’s ability to manage operating expenses, additional competition in the markets that Kamada competes, regulatory delays, and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”) and available at the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

This content was originally published on Benzinga. Read further disclosures here.

View the original release on www.newmediawire.com